Related Experiment Video
Updated: Apr 21, 2026
09:33
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
1.9K
Neuroblastoma: molecular pathogenesis and therapy.
Chrystal U Louis1, Jason M Shohet
1Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas 77030; email: culouis@txch.org , jmshohet@txch.org.
Annual Review of Medicine
|November 12, 2014
Summary
Neuroblastoma, a deadly pediatric cancer, is being intensely researched. Advances in understanding its biology and new targeted therapies offer hope for improved outcomes in young children.
Area of Science:
- Pediatric Oncology
- Developmental Biology
- Cancer Research
Background:
- Neuroblastoma is a pediatric cancer originating from the embryonic sympathoadrenal lineage.
- It is a leading cause of cancer death in children aged 1-5 years.
- Its aggressive nature and unique biology necessitate significant translational research.
Purpose of the Study:
- To review recent insights into neuroblastoma pathogenesis and biology.
- To contextualize these findings with current tumor biology and host interactions.
- To highlight advancements in classification and targeted therapies.
Main Methods:
- Review of recent scientific literature on neuroblastoma.
- Analysis of tumor biology, pathogenesis, and host interactions.
- Evaluation of novel therapeutic strategies and classification schemas.
Main Results:
- New insights into neuroblastoma biology are emerging.
- Development of novel classification systems is underway.
- Targeted therapies including small-molecule inhibitors and immunotherapies are advancing.
Conclusions:
- Systematic patient classification is crucial for effective treatment.
- Therapeutic advances hold promise for improved clinical outcomes.
- Further research into this aggressive pediatric malignancy is essential.
